TABLE 2.

Serological patterns and EBV diagnosis for the 12/32 serological patterns that occurred in ≥10 patients^a

Patternb no.	“Presumed” EBV diagnosis	BioPlex 2200 resulth					No. of patients							Predictivef value (%)
							In study	With EBV diagnosis based on medical record reviewc					Not reviewed
		VCA IgG	EBNA-1 IgG	EA-D IgG	VCA IgM	Het IgM		EBV naive	Primary acute	Past infection	Recovery/reactivation	Inconclusive
1	EBV naive	Neg	Neg	Neg	Neg	Neg	401	57	0	5	0	21	318d	68.7
2	Primary acute	Neg	Neg	Neg	Pos	Neg	17	7	6	3	1	0	0	35.3
4	Primary acute	Neg	Neg	Pos	Pos	Neg	10	0	4	1	0	2	3e	57.1
5	Primary acute	Neg	Neg	Neg	Pos	Pos	14	0	13	0	1	0	0	92.9
9	Primary acute	Neg	Neg	Pos	Pos	Pos	20	0	18	0	0	2	0	90.0
12	Past infection	Pos	Pos	Neg	Neg	Neg	892	1	0	171	1	9	710d	94.0
14	Past infection	Pos	Neg	Neg	Neg	Neg	33	2	1	22	1	7	0	66.7
15	Recov/React	Pos	Pos	Pos	Neg	Neg	306	3	0	232	0	63	8e	N/Cg
17	Recov/React	Pos	Pos	Neg	Pos	Neg	56	1	0	42	0	13	0	N/C
22	Recov/React	Pos	Pos	Pos	Pos	Neg	25	1	1	20	1	2	0	N/C
29	Unknown	Neg	Pos	Neg	Neg	Neg	24	12	0	6	0	5	1e	N/C
30	Unknown	Pos	Neg	Pos	Neg	Neg	12	0	1	6	0	5	0	N/C
Total							1,810	84	44	508	5	129	1,040

^aShown are the 12/32 possible serological patterns that occurred in ≥10 patients.

^bPattern numbers correspond to those shown in Table 1.

^cSee Materials and Methods for classification of EBV stage. Areas of expected concordance between the “presumed” and observed EBV stage are highlighted in bold.

^dTwenty percent of randomly selected patients were reviewed.

^ePatients were not reviewed due to unavailability of the medical record.

^fPredictive value was calculated by dividing the number of patients highlighted in bold by the total number of patients with completed chart review in that row.

^gN/C, not calculated. See Discussion.

^hPos, positive; Neg, negative.